Motif Bio PLC Presents at ID Week 2017
22 Giugno 2017 - 8:00AM
RNS Non-Regulatory
TIDMMTFB
Motif Bio PLC
22 June 2017
22 June 2017
Motif Bio plc
("Motif" or the "Company")
MOTIF BIO INVITED TO PRESENT AT INFECTIOUS DISEASES
CONFERENCE
Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical
company specialising in developing novel antibiotics, announces
that Dr. David Huang, Chief Medical Officer at Motif Bio, has been
invited to present a clinical development overview of iclaprim
during the formal Symposia session at IDWeek 2017 on October 5,
2017. In addition, Dr. Huang will lead a "Meet-the-Professors
Session" in a clinically oriented Q&A session on October 6,
2017.
IDWeek is the combined annual meeting of the Infectious Diseases
Society of America, Society for Healthcare Epidemiology of America,
HIV Medicine Association and Pediatric Infectious Diseases Society.
The Symposia session is focused on clinical programmes in late
clinical development and closest to regulatory approval.
Commenting on the invitation David Huang, CMO at Motif Bio said:
"IDWeek is a major event for infectious disease professionals and I
am delighted that the IDWeek Committee have selected iclaprim for
presentation. I look forward to presenting the positive data from
the REVIVE-1 trial. We believe these data suggest iclaprim may
serve as an important differentiated antibiotic option in an era of
emerging antibiotic resistant infections."
For further information please contact:
Motif Bio plc info@motifbio.com
Graham Lumsden (Chief
Executive Officer)
David Huang (Chief Medical
Officer)
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com
PR & IR) Mob: +44 (0)7980 541 893
Paul McManus Mob: +44 (0)7900 608 002
Mike Wort
MC Services AG (EUROPEAN
IR)
Raimund Gabriel +49 (0)89 210 2280
Notes to Editors
About iclaprim
Iclaprim is a potential novel antibiotic, designed to be
effective against bacteria that have developed resistance to other
antibiotics. Iclaprim exhibits potent activity against
Gram-positive clinical isolates of many genera of staphylococci,
including methicillin-sensitive staphylococci (MSSA) and
methicillin-resistant staphylococci (MRSA). The MIC(90) of iclaprim
was lower, demonstrating higher potency, than most comparators
including vancomycin and linezolid, standard of care therapies used
in serious and life-threatening Gram-positive hospital infections.
To date, iclaprim has been studied in over 1,000 patients and
healthy volunteers. No dosage adjustment is required in patients
with renal impairment, or in obese patients. The iclaprim fixed
dose may help reduce the resources required in hospitals since
dosage adjustment by health care professionals is avoided, and
overall hospital treatment costs may be lower, especially in
renally impaired patients
About Motif Bio
Motif Bio is a clinical-stage biopharmaceutical company, engaged
in the research and development of novel antibiotics designed to be
effective against serious and life-threatening infections in
hospitalised patients caused by multi-drug resistant bacteria. Our
lead product candidate, iclaprim, is being developed for the
treatment of acute bacterial skin and skin structure infections
(ABSSSI) and hospital acquired bacterial pneumonia (HABP),
including ventilator associated bacterial pneumonia (VABP),
infections often caused by MRSA (methicillin-resistant
Staphylococcus aureus). Having completed the REVIVE-1 trial,
patients are currently being enrolled and dosed in a second global
Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2
is expected in the second half of 2017.
IDWeek
Is attended by over 6000 healthcare professionals practicing or
involved in infectious diseases and healthcare epidemiology and
prevention, including researchers, clinicians, quality and patient
safety practitioners, epidemiologists. In addition, public health
officials, including those who see HIV and pediatric patients
attend in numbers. It is a meeting for professionals who want to
stay current and apply state-of-the art science to clinical care,
and excel in their own career.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGZVKMLGNZM
(END) Dow Jones Newswires
June 22, 2017 02:00 ET (06:00 GMT)
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Lug 2023 a Lug 2024